(Boston.com) — Decision Resources, a research and advisory firm for pharmaceutical and health care issues, said it projects that the hypertension drug market will decline as more generic alternatives become available.
Looking at the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan, Decision Resources said it expects the hypertension drug market to decline from $26 billion in 2009 to $23 billion in 2019.
Loading ...
Loading ...